World-renowned endocrinologist and Professor of Medicine, University of Toronto. Lead investigator of the landmark EMPA-REG OUTCOME trial that transformed cardio-renal-metabolic management in Type 2 Diabetes. Internationally recognized for his pioneering contributions to diabetes research and care.

Join us for an insightful session marking 11 years of the landmark EMPA-REG journey and its transformative impact on patient care. This session will explore the robust evidence supporting Empagliflozin and the Empagliflozin + Linagliptin combination across the Cardiovascular-Kidney-Metabolic (CKM) axis, highlighting their role in improving glycaemic control, protecting cardiorenal health, and redefining outcomes for people living with type 2 diabetes. Discover how a decade of evidence continues to shape clinical practice and deliver a lifetime of benefits for patients.

Dr. Prof Bernard Zinman

1

-

-

-

Upcoming Sessions